South Korea's three leading botulinum toxin manufacturers—Daewoong (Nabota), Medytox, and Hugel—posted combined Q2 revenue of ₩225.9 billion, with Nabota surpassing ₩100 billion in quarterly sales for the first time. The milestone reflects accelerating international demand, particularly in Middle East and Southeast Asian markets where Korean toxins have gained share against incumbent brands.
Market
South Korea's Big Three Post ₩225.9B Q2 Revenue
Nabota crosses ₩100 billion quarterly threshold as Korean toxin makers accelerate growth.
Nabota surpassed ₩100 billion in quarterly sales for the first time.
Medytox reported Q2 sales up 11% year-over-year, though operating profit declined 25%, signaling margin pressure from manufacturing and distribution costs. Hugel's first-half revenue reached ₩254.5 billion with operating profit of ₩103.7 billion, driven by overseas growth. The momentum underscores the competitive intensity in the global toxin market and the rising relevance of non-U.S. manufacturers in practice sourcing decisions.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.